ROVI announces the agreement with Sandoz to distribute and market its Enoxaparin biosimilar


No votes yet
 
Related
On his visit to the plant, which is ready to start production as soon as the authorisation from the Spanish Agency of Medicines and...
4 min
24/10/2022
Glicopepton Biotech founded to produce compounds of high technological value   · ROVI, Càrniques Celrà and Grupo Costa announce...
3 min
04/10/2022
ROVI tops the Sustainalytics sustainability ranking for the pharmaceutical subindustry worldwide Laboratorios Farmacéuticos ROVI...
2 min
01/08/2022